Adherence and completion in hepatitis C management: A systematic review

Gastroenterology Nursing

Volumn 36, Issue 1, 2013, Pages 53-58

  Redulla, Rhoda ^a   Dudley Brown, Sharon ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVIDENCE BASED MEDICINE; HEPATITIS C, CHRONIC; HUMAN; MEDICATION COMPLIANCE; HEPATITIS C; REVIEW;

EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE;

EID: 84873403998     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/SGA.0b013e318281634e     Document Type: Review

References (33)

1. Belfi ori, B., Ciliegi, P., Chiodera, A., Bacosi, D., Tosti, A., Baldelli, F., & Francisci, D. (2008) . Peginterferon plus ribavirin for chron-ic Hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digestive Liver Disease, 41 (4) , 303-307.
2. Cacoub, P., Ouzan, D., Melin, P., Lang, J. P., Rotily, M., Fontanges T., Marcellin, P. (2008) . Patient education improves adherence to peg-interferon and ribavirin in chronic Genotype 2 or 3 Hep-atitis C virus infection: A prospective, real-life, observational study. World Journal of Gastroenterology, 14 (40), 6195-6203.
3. Castera, L., Constant, A., Henry, C., Champbenoit, P., Bernard, P. H., De Ledinghen, V., Demotes-Mainard, J., & Cousigou, P. (2006) . Impact on adherence and sustained virological response of psychiatric side effects during peg interferon and ribavirin therapy for chronic Hepatitis C. Alimentary Pharmacology and Therapeutics, 24 (8), 1223-1230.
4. Centers for Disease Control. (2011). Hepatitis C Information for Health Professionals. Retrieved from http://www.cdc.gov/hepatitis/HCV/ index.htm.
5. Chou, R., Clark, E. C., & Helfand, M.; for the U.S. Preventive Services Task Force. (2004) . Screening for Hepatitis C virus infection: A re-view of the evidence for the U.S. Preventative Services Task Force. Annals of Internal Medicine, 140 (6), 465-479.
6. Cormier, M. (2005) . The role of Hepatitis C support groups. Gastro-enterology Nursing, 28 (3 Suppl.), S4-S9.
7. Evon, D., Verma, A., Simpson, K., Galanko, J., Dougherty, K., & Fried, M. (2008). Psychiatric symptoms during interferon treatment for Hepatitis C: Experiences from a tertiary care hepatology centre. Alimentary Pharmacology and Therapeutics, 27(11), 1071-1080.
8. Fahey, S. (2007). Developing a nursing service for patients with Hep-atitis C. Nursing Standards, 21(43), 35-40.
9. Fraenkel, L., McGraw, S., Wongcharatrawee, S., & Garcia-Tsao, G (2006) . Patients' experiences related to anti-viral treatment for Hepatitis C. Patient Education and Counseling, 62, 148-155.
10. Grebeley, J. (2007) . Integrating multiple programme and policy ap-proaches to Hepatitis C. International Journal of Drug Policy, 18 (5), 417-425.
11. Hashemi, N., Rossi, S., Navarro, V. J., & Herrine, S. K. (2008) . Safety of peginterferon in the treatment of chronic Hepatitis C. Expert Opinion on Drug Safety, 7 (6), 771-781.
12. Howell, C., Jeffers, L., Cassidy, W., Reddy, R., Hu, S., & Lee, J. (2006) Peginterferon alfa-2a and ribavirin for chronic Hepatitis C Genotype 1 infections in Black patients: Safety, tolerability and impact on sus-tained virologic response. Journal of Viral Hepatitis, 13 (6), 371-376.
13. Huckans, M. S., Loftis, J. M., Blackwell, A. D., Linke, A., & Hauser, P. (2007) . Interferon alpha therapy for Hepatitis C: Treatment completion and response rates among patients with substance use disorders. Substance Abuse Treatment, Prevention, & Policy, 2, 4.
14. Hussein, M., Benner, J. S., Lee, D., Sesti, A. M., Battleman, D. S., & Brock-Wood, C. (2010) . Propensity score matching in the evalu-ation of drug therapy management programs: An illustrative analysis program for patients with Hepatitis C virus. Quality Management in Health Care, 19 (1), 25-33.
15. Jeong, S. W., Kim, J. D., Woo, H. Y., You, C. R., Lee, S. W., Song, M. J., Yoon, S. K. (2009) . Impact of adherence to peg-interfer-on-ribavirin combination therapy in chronic Hepatitis C patients on achieving a sustained virologic response. Korean Journal of Hepatology, 15 (3), 338-349.
16. John-Baptiste, A., Varenbut, M., Lingley, M., Nedd-Roderique, T., Teplin, D., Tomlinson, G., Krahn, M. (2009) . Treatment of Hepatitis C infection for current or former substance abusers in a community setting. Journal of Viral Hepatitis, 16 (8), 557-567.
17. McHutchison, J., Manns, M., Patel, K., Poyhard, T, Lindsay, K. L., Trepo., C., International Hepatitis Interventional Therapy Group. (2002) . Adherence to combination therapy enhances sustained response in Genotype-1-infected patients with chronic Hepatitis C. Gastroenterology, 123 (4), 1061-1069.
18. McLaren, M., Garber, G., & Cooper, C. (2008). Barriers to Hepatitis C virus treatment in a Canadian HIV-Hepatitis C virus coinfec-tion tertiary care clinic. Canadian Journal of Gastroenterology, 22(2), 133-137.
19. Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G D., Vlahov, D., Thomas, D. L. (2008) . Limited uptake of HCV treatment among injection drug users. Journal of Community Health, 33 (3), 126-133.
20. Mira, J., Lopez-Cortes, L., Merino, D., Arizcorreta-Yarza, A., Rivero, A., Collado A., Pineda, J.; for the Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. (2007) . Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antiviral Therapy, 12, 1225-1235.
21. Neri, S., Pulvirenti, D., & Bertino, G. (2006) . Psychiatric symptoms induced by antiviral therapy in chronic Hepatitis C: Comparison between interferon-alpha-2a and interferon-alpha-2b. Clinical Drug Investigation, 26 (11), 655-662.
22. Newhouse, R., Dearholt, S., Poe, S., Pugh, L., & White, K. (2007) . Johns Hopkins Nursing Evidence-Based Practice Model and Guidelines. Indianapolis, IN : Sigma Theta Tau International.
23. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487-497.
24. Reau, N., Hadziyannis, S., Messinger, D., Fried, M. W., & Jensen, D. M. (2008) . Early predictors of anemia in patients with Hepatitis C Genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. American Journal of Gastroenterology, 103 (8), 1981-1988.
25. Rodgers, P. & Ruffi n, D. (1998). Medication nonadherence: Part II\-a pilot study in patients with congestive heart failure. Managed Care Interface, 11(9), 67-69.
26. Saunders, J. C., & Cookman, C. A. (2005) . A clarifi ed conceptual meaning of Hepatitis C-related depression. Gastroenterology Nursing, 28 (2), 23-29.
27. Schackman, B., Teixera, P., Weitzman, G., Mushlin, A., & Jacobson, I. (2008). Quality-of-life tradeoffs for Hepatitis C treatment: Do patients and providers agree? Medical Decision-Making, 28(2), 233-242.
28. Sikuler, E., Tur-Kaspa, R., Shemer-Avni, Y., Delgado, J., Zilberman, D., Baruch, Y., & Hyam, E. (2008) . Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV Genotype 2. Journal of Clinical Gastroenterology, 42 (73), 730-733.
29. Sylvestre, G., & Clements, B. J. (2007) . Adherence to Hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology and Hepatology, 19 (9), 741-747.
30. Sylvestre, G., & Zwebenc, J. E. (2007) . Integrating HCV services for drug users: A model to engagement and outcomes. International Journal on Drug Policy, 18 (5), 406-410.
31. Tanioka, D., Iwasaki, Y., Araki, Y., Osawa, T, Ikeda, H., Ando, M., Yamamoto, K. (2009) . Factors associated with com-bination therapy of interferon and ribavirin for patients with chronic Hepatitis C: importance of patient's motivation and physician's treatment experience. Liver International, 29 (5), 721-729.
32. Weiss, J., Bhatti, L., Dieterich, D., Edlin, B., Fishbein, & D., Goetz, M. (2008) . Hepatitis C patients' self-reported adherence to treat-ment with pegylated interferon and ribavirin. Alimentary Phar-macology & Therapeutics, 28 (3), 289-293.
33. Zickmund, S., Bryce, C., Blasiole, J., Shinkunas, L., LaBrecque, D., & Arnold R. (2006) . Majority of patients with Hepatitis C ex-press physical, mental, and social diffi culties with antiviral treat-ment. European Journal of Gastroenterology & Hepatology, 18 (4), 381-388.